Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Frigault

Showing results (71-80 of 117) with videos related to

Pageof 12
Sort By:
Blood|July 19, 2023
Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicityCharlotte E Graham, Won-Ho Lee, Hadley R Wiggin, et al.
Journal for Immunotherapy of Cancer|February 9, 2025
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registryDaniel J Landsburg, Matthew J Frigault, Michael Heim, et al.
Journal for Immunotherapy of Cancer|November 16, 2019
CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastomaBryan D Choi, Xiaoling Yu, Ana P Castano, et al.
Transplantation and Cellular Therapy|November 14, 2025
CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World SettingBradley D Hunter, Matthew Lunning, Mazyar Shadman, et al.
American Journal of Hematology|October 23, 2024
Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosisLeon D Kaulen, Philipp Karschnia, Sofia Doubrovinskaia, et al.
The Lancet. Oncology|April 3, 2025
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeCharlotte E Graham, Roser Velasco, Ana Alarcon Tomas, et al.
The Lancet. Haematology|October 13, 2022
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trialReuben Benjamin, Nitin Jain, Marcela V Maus, et al.
Cancer Immunology Research|January 21, 2015
Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cellsMatthew J Frigault, Jihyun Lee, Maria Ciocca Basil, et al.
Journal for Immunotherapy of Cancer|September 9, 2020
Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sourcesAndrea Schmidts, Leah C Marsh, Ambike A Srivastava, et al.
Blood|March 19, 2025
Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCTZachariah DeFilipp, Haesook T Kim, Laura W Knight, et al.
Pageof 12

Showing results (71-80 of 117) with videos related to

Sort By:
Pageof 12
Blood|July 19, 2023
Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicityCharlotte E Graham, Won-Ho Lee, Hadley R Wiggin, et al.
Journal for Immunotherapy of Cancer|February 9, 2025
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registryDaniel J Landsburg, Matthew J Frigault, Michael Heim, et al.
Journal for Immunotherapy of Cancer|November 16, 2019
CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastomaBryan D Choi, Xiaoling Yu, Ana P Castano, et al.
Transplantation and Cellular Therapy|November 14, 2025
CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World SettingBradley D Hunter, Matthew Lunning, Mazyar Shadman, et al.
American Journal of Hematology|October 23, 2024
Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosisLeon D Kaulen, Philipp Karschnia, Sofia Doubrovinskaia, et al.
The Lancet. Oncology|April 3, 2025
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeCharlotte E Graham, Roser Velasco, Ana Alarcon Tomas, et al.
The Lancet. Haematology|October 13, 2022
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trialReuben Benjamin, Nitin Jain, Marcela V Maus, et al.
Cancer Immunology Research|January 21, 2015
Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cellsMatthew J Frigault, Jihyun Lee, Maria Ciocca Basil, et al.
Journal for Immunotherapy of Cancer|September 9, 2020
Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sourcesAndrea Schmidts, Leah C Marsh, Ambike A Srivastava, et al.
Blood|March 19, 2025
Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCTZachariah DeFilipp, Haesook T Kim, Laura W Knight, et al.
Pageof 12